These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 25424816)
1. Study on the effectiveness and impact of pentavalent vaccination program in India and other south Asian countries. Sreedhar S; Antony A; Poulose N Hum Vaccin Immunother; 2014; 10(7):2062-5. PubMed ID: 25424816 [TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine. Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and reactogenicity of a combined fully liquid DTPw-HepB-Hib pentavalent vaccine in healthy infants: no clinically relevant impact of a birth dose of hepatitis B vaccine. Gentile A; Umido V; Czerniuk P; Nacul J; Seigelchifer M; Hilbert AK; Yela U; Herzog C; Aeberhard U; Spyr C Int J Infect Dis; 2011 Jan; 15(1):e24-9. PubMed ID: 21093342 [TBL] [Abstract][Full Text] [Related]
4. Safety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwp-HepB-Hib vaccine in healthy Indian toddlers and infants. Gandhi DJ; Dhaded SM; Ravi MD; Dubey AP; Kundu R; Lalwani SK; Chhatwal J; Mathew LG; Gupta M; Sharma SD; Bavdekar SB; Jayanth MV; Ravinuthala S; Sil A; Dhingra MS Hum Vaccin Immunother; 2016 Apr; 12(4):946-54. PubMed ID: 26580093 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine. Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088 [TBL] [Abstract][Full Text] [Related]
6. A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age. Thollot F; Scheifele D; Pankow-Culot H; Cheuvart B; Leyssen M; Ulianov L; Miller JM Pediatr Infect Dis J; 2014 Dec; 33(12):1246-54. PubMed ID: 25037033 [TBL] [Abstract][Full Text] [Related]
7. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age. Szenborn L; Czajka H; Brzostek J; Konior R; Caubet M; Ulianov L; Leyssen M Pediatr Infect Dis J; 2013 Jul; 32(7):777-85. PubMed ID: 23838777 [TBL] [Abstract][Full Text] [Related]
8. Four is better than nine. a combined diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine for routine immunization in Malaysia. Wong SL; Soosai P; Teoh YL; Han HH; Lefevre I; Bock HL Southeast Asian J Trop Med Public Health; 2008 May; 39(3):474-83. PubMed ID: 18564687 [TBL] [Abstract][Full Text] [Related]
9. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content. Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170 [TBL] [Abstract][Full Text] [Related]
10. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Heininger U; ; ; Sänger R; Jacquet JM; Schuerman L Vaccine; 2007 Jan; 25(6):1055-63. PubMed ID: 17049692 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age. Diaz-Mitoma F; Halperin SA; Tapiero B; Hoffenbach A; Zappacosta PS; Radley D; Bradshaw S; Martin JC; Boslego JW; Hesley TM; Bhuyan PK; Silber JL Vaccine; 2011 Feb; 29(6):1324-31. PubMed ID: 21134456 [TBL] [Abstract][Full Text] [Related]
12. Antibody persistence of two pentavalent DTwP-HB-Hib vaccines to the age of 15-18 months, and response to the booster dose of quadrivalent DTwP-Hib vaccine. Sharma H; Yadav S; Lalwani S; Kapre S; Jadhav S; Parekh S; Palkar S; Ravetkar S; Bahl S; Kumar R; Shewale S Vaccine; 2013 Jan; 31(3):444-7. PubMed ID: 23196204 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age. Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057 [TBL] [Abstract][Full Text] [Related]
14. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine. Nolan T; Altmann A; Skeljo M; Streeton C; Schuerman L Vaccine; 2004 Nov; 23(1):14-20. PubMed ID: 15519702 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Gimenez-Sanchez F; Kieninger DM; Kueper K; Martinon-Torres F; Bernaola E; Diez-Domingo J; Steul K; Juergens C; Gurtman A; Giardina P; Liang JZ; Gruber WC; Emini EA; Scott DA; Vaccine; 2011 Aug; 29(35):6042-8. PubMed ID: 21704105 [TBL] [Abstract][Full Text] [Related]
16. Development and introduction of a ready-to-use pediatric pentavalent vaccine to meet and sustain the needs of developing countries--Quinvaxem®: the first 5 years. Schmid DA; Macura-Biegun A; Rauscher M Vaccine; 2012 Sep; 30(44):6241-8. PubMed ID: 22889824 [TBL] [Abstract][Full Text] [Related]
17. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants. Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants. Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216 [TBL] [Abstract][Full Text] [Related]
20. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic. Marshall H; McIntyre P; Roberton D; Dinan L; Hardt K Int J Infect Dis; 2010 Jan; 14(1):e41-9. PubMed ID: 19467896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]